Compare MRKR & GFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MRKR | GFAI |
|---|---|---|
| Founded | 1999 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.7M | 15.9M |
| IPO Year | 2010 | 2020 |
| Metric | MRKR | GFAI |
|---|---|---|
| Price | $1.21 | $0.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $10.00 | $4.50 |
| AVG Volume (30 Days) | 84.0K | ★ 194.0K |
| Earning Date | 05-14-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 33.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $14.12 |
| Revenue Next Year | $936.27 | $10.25 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.84 | $0.31 |
| 52 Week High | $2.46 | $1.38 |
| Indicator | MRKR | GFAI |
|---|---|---|
| Relative Strength Index (RSI) | 44.33 | 45.74 |
| Support Level | $1.10 | $0.31 |
| Resistance Level | $1.36 | $0.42 |
| Average True Range (ATR) | 0.12 | 0.03 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 4.76 | 8.58 |
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from MAR-T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells. These T cells are designed to recognize multiple tumor targets to produce broad spectrum anti-tumor activity. Its pipeline products include: Autologous MAR-T cell product for the treatment of lymphoma and pancreatic cancer (MT-601), and Off-the-Shelf (OTS) products (MT-401-OTS).
Guardforce AI Co Ltd is an integrated solution provider, specializing in security solutions, and also focuses on implementing AI and robotics solutions to improve business operational efficiency and sales and marketing processes, especially for the retail and travel industry in the Asia Pacific region. The company's operating business segments include Secured Logistics, AI & Robotics Solution Business, and Corporate and others. The majority of its revenue is generated from the Secured Logistics segment, which includes services like cash-in-transit, dedicated vehicles to banks, ATM management, cash center operations, cash processing, coin processing, cheque center, and cash deposit machine solutions. Geographically, the company generates maximum revenue from Thailand.